Suresh Shelat

Immuno-oncology Cellular Therapy Clinical Development, Sr Medical Director @Bristol Myers Squibb

Led Phase I-IV immuno-oncology trials with cellular therapy anti-BCMA CAR-T ABECMA (idecabtagene vicleucel), alnuctamab, EMPLICITI (elotuzumab) in multiple myeloma, leading to successful BLA.• Program leader for SPRYCEL/dasatinib in pediatric chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), and assets in immunology/inflammation, and fibrosis, leading to NDA.• Leveraging Digital Health technologies and artificial intelligence/machine learning (AI/ML) to enable smaller, shorter, and less costly decentralized clinical trials (DCT) trials with earlier adverse event detection through remote patient monitoring (RPM), and improved diagnostic performance.